TY - JOUR AU - J-m, L. AU - Ivy, S. P. AU - Kohn, E. C. PY - 2016 DA - 2016// TI - Challenges and opportunities for immunotherapies in gynecologic cancers JO - Oncology New York VL - 30 ID - J-m2016 ER - TY - JOUR AU - Mouw, K. W. AU - Goldberg, M. S. AU - Konstantinopoulos, P. A. AU - D'Andrea, A. D. PY - 2017 DA - 2017// TI - DNA damage and repair biomarkers of immunotherapy response JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-17-0226 DO - 10.1158/2159-8290.CD-17-0226 ID - Mouw2017 ER - TY - JOUR AU - Hellmann, M. D. AU - Nathanson, T. AU - Rizvi, H. PY - 2018 DA - 2018// TI - Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung Cancer JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2018.03.018 DO - 10.1016/j.ccell.2018.03.018 ID - Hellmann2018 ER - TY - JOUR AU - Jiao, S. AU - Xia, W. AU - Yamaguchi, H. PY - 2017 DA - 2017// TI - PARP inhibitor upregulates PD-L1 expression and enhances Cancer-associated immunosuppression JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-3215 DO - 10.1158/1078-0432.CCR-16-3215 ID - Jiao2017 ER - TY - STD TI - Sun C, Fang Y, Yin J, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017;9(392). ID - ref5 ER - TY - JOUR AU - Hegan, D. C. AU - Lu, Y. AU - Stachelek, G. C. AU - Crosby, M. E. AU - Bindra, R. S. AU - Glazer, P. M. PY - 2010 DA - 2010// TI - Inhibition of poly (ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130 JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.0904783107 DO - 10.1073/pnas.0904783107 ID - Hegan2010 ER - TY - JOUR AU - Kandalaft, L. E. AU - Motz, G. T. AU - Busch, J. AU - Coukos, G. PY - 2011 DA - 2011// TI - Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin JO - Cancer Immunol Immunother VL - 344 UR - https://doi.org/10.1007/82_2010_95 DO - 10.1007/82_2010_95 ID - Kandalaft2011 ER - TY - JOUR AU - Liu, J. F. AU - Barry, W. T. AU - Birrer, M. PY - 2014 DA - 2014// TI - Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70391-2 DO - 10.1016/S1470-2045(14)70391-2 ID - Liu2014 ER - TY - JOUR AU - Munoz-Unceta, N. AU - Burgueno, I. AU - Jimenez, E. AU - Paz-Ares, L. PY - 2018 DA - 2018// TI - Durvalumab in NSCLC: latest evidence and clinical potential JO - Ther Adv Med Oncol VL - 10 UR - https://doi.org/10.1177/1758835918804151 DO - 10.1177/1758835918804151 ID - Munoz-Unceta2018 ER - TY - JOUR AU - Lee, J. -. M. AU - Cimino-Mathews, A. AU - Peer, C. J. PY - 2017 DA - 2017// TI - Safety and clinical activity of the programmed death-ligand 1 inhibitor Durvalumab in combination with poly (ADP-ribose) polymerase inhibitor Olaparib or vascular endothelial growth factor receptor 1-3 inhibitor Cediranib in Women’s cancers: a dose-escalation, phase I study JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.72.1340 DO - 10.1200/JCO.2016.72.1340 ID - Lee2017 ER - TY - JOUR AU - Roth, J. e. f. f. r. e. y. AU - Peer, C. o. d. y. AU - Mannargudi, B. a. s. k. a. r. AU - Swaisland, H. e. l. e. n. AU - Lee, J. u. n. g. -. M. i. n. AU - Kohn, E. l. i. s. e. AU - Figg, W. i. l. l. i. a. m. PY - 2014 DA - 2014// TI - A Sensitive and Robust Ultra HPLC Assay with Tandem Mass Spectrometric Detection for the Quantitation of the PARP Inhibitor Olaparib (AZD2281) in Human Plasma for Pharmacokinetic Application JO - Chromatography VL - 1 UR - https://doi.org/10.3390/chromatography1020082 DO - 10.3390/chromatography1020082 ID - Roth2014 ER - TY - JOUR AU - Rajan, A. AU - Carter, C. A. AU - Berman, A. PY - 2014 DA - 2014// TI - Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70596-5 DO - 10.1016/S1470-2045(13)70596-5 ID - Rajan2014 ER - TY - JOUR AU - Tomita, Y. AU - Lee, M. J. AU - Lee, S. PY - 2016 DA - 2016// TI - The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat JO - Oncoimmunology VL - 5 UR - https://doi.org/10.1080/2162402X.2016.1219008 DO - 10.1080/2162402X.2016.1219008 ID - Tomita2016 ER - TY - JOUR AU - Lee, J. -. M. AU - Trepel, J. B. AU - Choyke, P. PY - 2015 DA - 2015// TI - CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer JO - Front Oncol VL - 5 UR - https://doi.org/10.3389/fonc.2015.00123 DO - 10.3389/fonc.2015.00123 ID - Lee2015 ER - TY - JOUR AU - Gelmon, K. A. AU - Tischkowitz, M. AU - Mackay, H. PY - 2011 DA - 2011// TI - Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70214-5 DO - 10.1016/S1470-2045(11)70214-5 ID - Gelmon2011 ER - TY - JOUR AU - Matulonis, U. A. AU - Berlin, S. AU - Ivy, P. PY - 2009 DA - 2009// TI - Cediranib, an Oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal Cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.23.2777 DO - 10.1200/JCO.2009.23.2777 ID - Matulonis2009 ER - TY - JOUR AU - Konstantinopoulos, P. AU - Munster, P. AU - Forero-Torez, A. PY - 2018 DA - 2018// TI - Topacio: preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab JO - Gynecol Oncol VL - 149 UR - https://doi.org/10.1016/j.ygyno.2018.04.554 DO - 10.1016/j.ygyno.2018.04.554 ID - Konstantinopoulos2018 ER - TY - JOUR AU - Drew, Y. AU - Jonge, M. AU - Hong, S. PY - 2018 DA - 2018// TI - An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC) JO - Gynecol Oncol VL - 149 UR - https://doi.org/10.1016/j.ygyno.2018.04.555 DO - 10.1016/j.ygyno.2018.04.555 ID - Drew2018 ER - TY - JOUR AU - Lee, J. AU - Annunziata, C. AU - Houston, N. PY - 2018 DA - 2018// TI - A phase 2 study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa) JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdx768 DO - 10.1093/annonc/mdx768 ID - Lee2018 ER - TY - STD TI - Liu J, Herold C, Luo W, et al. A phase 2 trial of combination nivolumab and bevacizumab in recurrent ovarian cancer. Ann Oncol. 2018;29. ID - ref20 ER - TY - JOUR AU - Varga, A. n. d. r. e. a. AU - Piha-Paul, S. a. r. i. n. a. A. n. n. e. AU - Ott, P. a. t. r. i. c. k. A. l. e. x. a. n. d. e. r. AU - Mehnert, J. a. n. i. c. e. M. AU - Berton-Rigaud, D. o. m. i. n. i. q. u. e. AU - Morosky, A. n. n. e. AU - Zhao, G. u. o. Q. i. n. g. AU - Rangwala, R. e. s. h. m. a. A. AU - Matei, D. a. n. i. e. l. a. PY - 2017 DA - 2017// TI - Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028 JO - Journal of Clinical Oncology VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.5513 DO - 10.1200/JCO.2017.35.15_suppl.5513 ID - Varga2017 ER - TY - STD TI - Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer. N Engl J Med. 2018. ID - ref22 ER - TY - JOUR AU - Liu, D. AU - Wang, S. AU - Bindeman, W. PY - 2017 DA - 2017// TI - Clinical applications of PD-L1 bioassays for cancer immunotherapy JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0479-y DO - 10.1186/s13045-017-0479-y ID - Liu2017 ER - TY - JOUR AU - Hirsch, F. R. AU - McElhinny, A. AU - Stanforth, D. PY - 2017 DA - 2017// TI - PD-L1 immunohistochemistry assays for lung Cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2016.11.2228 DO - 10.1016/j.jtho.2016.11.2228 ID - Hirsch2017 ER - TY - JOUR AU - Vilain, R. E. AU - Menzies, A. M. AU - Wilmott, J. S. PY - 2017 DA - 2017// TI - Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-0698 DO - 10.1158/1078-0432.CCR-16-0698 ID - Vilain2017 ER -